Page 86 - Read Online

Nickoloff et al. Cancer Drug Resist 2021;4:244-63 I http://dx.doi.org/10.20517/cdr.2020.89 Page 262

fork-associated DNA damage repair. Mol Cancer Res 2017;15:1503-16.
191. Amunugama R, Fishel R. Homologous recombination in eukaryotes. Prog Mol Biol Transl Sci 2012;110:155-206.
192. Shrivastav M, Miller CA, De Haro LP, et al. DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair 2009;8:920-9.
193. Nickoloff JA, Brenneman MA. Analysis of recombinational repair of DNA double-strand breaks in mammalian cells with I-SceI nuclease.
Methods Mol Biol 2004;262:35-52.
194. Yoshino Y, Endo S, Chen Z, et al. Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene
editing efficiency. Sci Rep 2019;9:1644.
195. Price BD, D’Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell 2013;152:1344-54.
196. Kaushal S, Freudenreich CH. The role of fork stalling and DNA structures in causing chromosome fragility. Genes Chromosomes Cancer
2019;58:270-83.
197. Wray J, Liu J, Nickoloff JA, Shen Z. Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication
stress. Cancer Res 2008;68:2699-707.
198. Groth P, Orta ML, Elvers I, et al. Homologous recombination repairs secondary replication induced DNA double-strand breaks after
ionizing radiation. Nucleic Acids Res 2012;40:6585-94.
199. Murnane JP. Telomere dysfunction and chromosome instability. Mutat Res 2012;730:28-36.
200. Budke B, Logan HL, Kalin JH, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.
Nucleic Acids Res 2012;40:7347-57.
201. Budke B, Lv W, Kozikowski AP, Connell PP. Recent developments using small molecules to target RAD51: How to best modulate
RAD51 for anticancer therapy? ChemMedChem 2016;11:2468-73.
202. Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of small molecules that specifically inhibit the D-loop activity
of RAD51. J Med Chem 2016;59:4511-25.
203. Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer
2015;121:269-75.
204. Sekhar D, Pooja S, Kumar S, Rajender S. RAD51 135G > C substitution increases breast cancer risk in an ethnic-specific manner: a meta-
analysis on 21,236 cases and 19,407 controls. Sci Rep 2015;5:11588.
205. Evans MK, Longo DL. PALB2 mutations and breast-cancer risk. N Engl J Med 2014;371:566-8.
206. Jette NR, Kumar M, Radhamani S, et al. ATM-deficient cancers provide new opportunities for precision oncology. Cancers 2020;12:687.
207. Byrum AK, Vindigni A, Mosammaparast N. Defining and modulating ‘BRCAness’. Trends Cell Biol 2019;29:740-51.
208. Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med
2016;8:362ps17.
209. Yi M, Dong B, Qin S, et al. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 2019;8:29.
210. del Rivero J, Kohn EC. PARP inhibitors: the cornerstone of DNA repair-targeted therapies. Oncology 2017;31:265-73.
211. Gil Del Alcazar CR, Todorova PK, Habib AA, Mukherjee B, Burma S. Augmented HR repair mediates acquired temozolomide resistance
in glioblastoma. Mol Cancer Res 2016;14:928-40.
212. Zhang X, Ma N, Yao W, Li S, Ren Z. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer.
Cancer Cell Int 2019;19:356.
213. Liu X, Han EK, Anderson M, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both
base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009;7:1686-92.
214. Noordermeer SM, van Attikum H. PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells. Trends Cell Biol 2019;29:820-34.
215. D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 2018;71:172-6.
216. Tian H, Gao Z, Li H, et al. DNA damage response--a double-edged sword in cancer prevention and cancer therapy. Cancer Lett
2015;358:8-16.
217. Bakr A, Oing C, Kocher S, et al. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament
formation. Nucleic Acids Res 2015;43:3154-66.
218. Ahlskog JK, Larsen BD, Achanta K, Sorensen CS. ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. EMBO
Rep 2016;17:671-81.
219. Jackson SP, Helleday T. Drugging DNA repair. Science 2016;352:1178-9.
220. Glorieux M, Dok R, Nuyts S. Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers. Oncotarget
2017;8:81662-78.
221. Riches LC, Trinidad AG, Hughes G, et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib
responses preclinically. Mol Cancer Ther 2020;19:13-25.
222. Zhou C, Parsons JL. The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma. Expert Rev Mol Med
2020;22:e3.
223. Ferri A, Stagni V, Barila D. Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma. Int J Mol Sci
2020;21:4910.
224. Philip CA, Laskov I, Beauchamp MC, et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP
inhibitors. BMC Cancer 2017;17:638.
225. Wang D, Li C, Zhang Y, et al. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type
PIK3CA genes. Gynecol Oncol 2016;142:548-56.
226. Cossar LH, Schache AG, Risk JM, et al. Modulating the DNA damage response to improve treatment response in cervical cancer. Clin